Diabetes Insipidus — Central and Nephrogenic

Diabetes insipidus (DI) is a disorder of water homeostasis characterized by the inability to concentrate urine, resulting in polyuria (>3 L/day) and polydipsia. The condition results from either insufficient production or action of antidiuretic hormone (ADH, vasopressin), distinguishing it from diabetes mellitus, which involves glucose metabolism. Central DI results from ADH deficiency due to hypothalamic-pituitary dysfunction, whereas nephrogenic DI reflects kidney resistance to normal or elevated ADH levels. Though rare (incidence 1-4 per 100,000), DI carries significant morbidity if untreated, with risk of severe dehydration, hypernatremia, and neurologic complications. Recognition is essential for boards, as DI presentations can mimic polycystic kidney disease, psychogenic polydipsia, or uncontrolled diabetes mellitus, and the diagnostic algorithm distinguishes these entities efficiently. Understanding the pathophysiology of water reabsorption in the collecting duct and the hypothalamic-pituitary-renal axis is fundamental to clinical problem-solving.

ADH (vasopressin) is a 9-amino acid neuropeptide synthesized in the supraoptic and paraventricular nuclei of the hypothalamus and stored in neurosecretory granules within nerve terminals of the posterior pituitary. Upon stimulation by hypertonicity (detected by osmoreceptors in the supraoptic nucleus), hypovolemia (via baroreceptors), or pain/stress, ADH is released into the systemic circulation where it binds to V2 receptors on the basolateral membrane of collecting duct principal cells. This V2 receptor-mediated signaling activates adenylyl cyclase through Gs-coupled G-proteins, increasing intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylates aquaporin-2 (AQP2) water channels, triggering translocation of AQP2 from intracellular vesicles to the apical membrane, permitting water reabsorption driven by the osmotic gradient established by the countercurrent multiplier system in the loop of Henle and vasa recta. In the absence of ADH, AQP2 channels remain sequestered intracellularly, and the collecting duct becomes impermeable to water, resulting in dilute urine and polyuria. This system achieves plasma osmolality regulation within a narrow range (280-295 mOsm/kg).

Central DI arises from destruction, dysfunction, or interruption of hypothalamic-pituitary structures essential for ADH synthesis or release. Pathologic processes causing >80-90% loss of ADH-secreting neurons (pituitary or supraoptic/paraventricular nuclei) result in symptomatic central DI. Common mechanisms include: (1) surgical hypophysectomy or pituitary stalk section, which severs the hypothalamic-hypophyseal tract; (2) pituitary tumors (craniopharyngioma, prolactinoma, adenomas) causing mass effect or infiltration; (3) infiltrative/inflammatory conditions (sarcoidosis, histiocytosis X, tuberculosis, lymphocytic hypophysitis) damaging pituitary tissue; (4) head trauma with pituitary stalk disruption; (5) primary CNS lymphoma or leukemic infiltration; and (6) idiopathic forms with presumed autoimmune destruction of vasopressinergic neurons. Genetic mutations in the AVP gene (encoding prevasopressin) or NEUROPHYSIN II cause familial central DI via autosomal dominant inheritance with incomplete penetrance and variable expressivity. The clinical consequence is insufficient ADH secretion despite appropriate osmotic or hemodynamic stimulus, preventing the normal physiologic increase in collecting duct water permeability and resulting in obligatory polyuria and secondary polydipsia as the patient attempts to maintain plasma osmolality.

Nephrogenic DI occurs when the kidneys fail to respond appropriately to circulating ADH, despite normal or elevated hormone levels. The molecular defects involve either: (1) V2 receptor dysfunction, primarily through X-linked loss-of-function mutations in AVPR2 (ADH receptor 2 gene), affecting ~80% of congenital nephrogenic DI cases and causing impaired signal transduction; (2) aquaporin-2 mutations, less common but causing autosomal recessive or dominant forms of congenital nephrogenic DI, preventing proper localization or function of water channels; (3) impaired cAMP generation or signaling due to mutations in PKA-encoding genes or defects in adenylyl cyclase; and (4) acquired forms from medullary dysfunction caused by chronic hypokalemia (which impairs aquaporin-2 trafficking and causes medullary atrophy), chronic hypercalcemia (which damages collecting duct epithelium and increases prostaglandin synthesis that antagonizes ADH), lithium toxicity (which uncouples V2 receptor signaling through multiple mechanisms including altered phosphoinositide metabolism), and conditions causing medullary washout such as loop diuretic use or nephrotic syndrome. In nephrogenic DI, ADH binding to V2 receptors fails to trigger sufficient AQP2 translocation or function, rendering the collecting duct persistently impermeable to water despite adequate or excessive hormone stimulus. The kidneys cannot concentrate urine despite high circulating vasopressin levels, distinguishing this entity diagnostically and therapeutically from central DI.

Both forms of DI result in polyuria with dilute urine (osmolality <300 mOsm/kg, typically 50-200 mOsm/kg) and obligatory water loss exceeding electrolyte loss. If thirst mechanisms remain intact and free water access is available, patients develop secondary polydipsia and maintain relatively normal plasma osmolality (often 280-310 mOsm/kg) at the expense of consuming 5-20 L of fluid daily. However, if fluid intake is restricted, or in infants/elderly/unconscious patients without access to water, hypernatremia (Na+ >145 mEq/L) and hypertonicity develop, triggering ADH release (in central DI) or further exacerbating polyuria (in nephrogenic DI). Chronic polyuria may lead to dilated collecting ducts and ureter (hydroureter), mimicking obstructive uropathy on imaging. The constant osmotic load from urine dilution creates a fluid shift gradient; in central DI, ADH replacement restores concentrating ability and normalizes polyuria within hours to days, whereas nephrogenic DI shows minimal or absent response to exogenous ADH, distinguishing the two mechanistically.

Surgical and Traumatic: Hypophysectomy, transsphenoidal pituitary surgery, pituitary stalk section, and severe head trauma (closed or penetrating) account for ~30-40% of central DI cases. Post-surgical central DI may be transient (resolving within days to weeks as ADH-secreting neurons recover) or permanent if >90% of pituitary tissue is destroyed. Traumatic DI often follows a triphasic pattern: acute polyuria (from pituitary damage), followed by temporary oliguria (from massive ADH release and cerebral edema), then recurrent polyuria if neuronal damage is severe.

Pituitary and Sellar Masses: Craniopharyngioma (most common pediatric sellar tumor) causes central DI in 10-15% of cases through mass effect or infiltration. Pituitary adenomas (prolactin-secreting, growth hormone-secreting, or non-functioning) cause DI in 5% of cases, particularly large macroadenomas compressing the pituitary stalk. Other tumors include suprasellar meningiomas, optic pathway gliomas, and metastatic disease.

Infiltrative and Inflammatory Disorders: Neurosarcoidosis affects the hypothalamic-pituitary region in 1-2% of sarcoidosis patients, causing granulomatous infiltration. Lymphocytic hypophysitis (autoimmune inflammation of the pituitary) causes central DI, more common in women and sometimes associated with pregnancy or postpartum period. Tuberculosis, fungal infections (histoplasmosis, cryptococcosis, coccidioidomycosis), and leukemic/lymphomatous infiltration are important infectious and neoplastic causes. Histiocytosis X (Langerhans cell histiocytosis) causes DI through infiltration of the hypothalamic-pituitary region, particularly in children.

Idiopathic Central DI: Approximately 30-50% of central DI cases are idiopathic, with suspected autoimmune destruction of vasopressinergic neurons, supported by detection of anti-vasopressin cell antibodies in some patients. Idiopathic disease typically presents in young to middle-aged adults.

Familial Central DI: Autosomal dominant mutations in the AVP (prevasopressin) gene or NEUROPHYSIN II cause ~5% of congenital central DI. These mutations result in intracellular accumulation of misfolded prevasopressin, triggering endoplasmic reticulum stress and apoptosis of vasopressinergic neurons. Onset typically occurs in early childhood with progressive worsening through the first decade of life as more neurons are damaged. Wolfram syndrome (DIDMOAD: Diabetes Insipidus, Diabetes Mellitus, Optic atrophy, Deafness) results from mutations in the WFS1 gene encoding an endoplasmic reticulum chaperone protein; affected patients develop central DI in conjunction with insulin-dependent diabetes mellitus, progressive blindness, and sensorineural hearing loss.

X-Linked Nephrogenic DI: AVPR2 mutations causing loss-of-function of the V2 receptor account for ~80% of congenital nephrogenic DI, inherited in an X-linked recessive pattern. Affected males present with severe polyuria in infancy; heterozygous females are typically asymptomatic but may show mild concentrating defects. Over 200 distinct AVPR2 mutations have been identified, most causing complete or partial receptor dysfunction.

Autosomal Recessive and Autosomal Dominant Forms: Mutations in AQP2 (aquaporin-2 gene) cause autosomal recessive nephrogenic DI when both alleles are affected, or autosomal dominant nephrogenic DI when heterozygous mutations disrupt aquaporin-2 trafficking or tetramer assembly. AQP2 mutations account for ~10-20% of congenital nephrogenic DI. Rarely, mutations in genes encoding other signaling proteins (adenylyl cyclase, PKA regulatory subunits) cause familial nephrogenic DI.

Medications: Lithium is the most common drug cause of acquired nephrogenic DI, occurring in 20-40% of patients on chronic lithium therapy. Lithium accumulates in collecting duct cells and impairs phosphoinositide metabolism downstream of V2 receptor signaling, also causing chronic interstitial nephritis. Loop diuretics (furosemide) impair the countercurrent multiplier mechanism and cause medullary washout, reducing the osmotic gradient driving water reabsorption. NSAIDs reduce renal prostaglandin synthesis, which modulates ADH responsiveness. Amphotericin B causes direct tubular toxicity. Cisplatin, topiramate, demeclocycline, and ifosfamide are additional medicinal causes.

Electrolyte Disorders: Chronic hypokalemia (serum K+ <3 mEq/L) from diuretics, diarrhea, or vomiting impairs aquaporin-2 expression and trafficking, disrupts medullary osmolality by causing medullary atrophy, and prevents ADH-mediated water reabsorption even with ADH replacement. Chronic hypercalcemia (>11 mg/dL sustained) from hyperparathyroidism, vitamin D intoxication, or malignancy damages collecting duct epithelium, increases urinary prostaglandins that antagonize ADH, and impairs aquaporin-2 function. Resolution of hypokalemia or hypercalcemia may partially restore concentrating ability.

Renal and Systemic Diseases: Chronic kidney disease with reduced nephron mass impairs the ability to generate or maintain the medullary osmotic gradient. Polycystic kidney disease (both autosomal dominant and recessive forms) causes nephrogenic DI through cyst-related medullary disruption. Pyelonephritis and other chronic infections damage the medulla. Post-obstructive diuresis after relief of bilateral ureteral obstruction may cause transient nephrogenic-like polyuria. Sickle cell disease damages the vasa recta and medullary vasculature, impairing gradient generation.

Pregnancy-Associated Nephrogenic DI: Gestational transient nephrogenic DI occurs in rare pregnancies due to increased placental vasopressinase (an enzyme degrading ADH) or altered V2 receptor sensitivity. Resolves postpartum.

Polyuria: The hallmark of DI is excessive urination with urine output typically 3-20 L/day (normal 1-2 L/day), often with a peculiar pattern of very frequent, small-volume voids interspersed with occasional large volumes. Patients often report nocturia 5-10+ times per night, significantly disrupting sleep quality. The polyuria results directly from the inability to reabsorb filtered water in the collecting duct, driving osmotic diuresis. In central DI, polyuria can develop acutely over hours (post-traumatic or post-surgical) or insidiously over weeks to months (idiopathic or infiltrative); in nephrogenic DI, onset is typically insidious unless precipitated by a new medication or electrolyte derangement.

Polydipsia: Intense thirst accompanying polyuria drives compensatory fluid consumption of 5-20 L/day. Patients describe an insatiable thirst even immediately after drinking large quantities of fluid. The thirst reflects the osmoreceptor-mediated response to rising plasma osmolality from obligatory urinary water loss. Patients often report a preference for ice water or ice chips. In central DI, thirst may be blunted acutely if pituitary dysfunction also damages osmoregulatory neurons; in such cases, hypernatremia can develop insidiously.

Dehydration and Hypernatremia (if fluid access restricted): If free water access is unavailable (infants, hospitalized patients, unconscious patients), obligatory urinary water loss exceeds intake, leading to progressive dehydration and hypernatremia (serum Na+ >145 mEq/L). Symptoms of hypernatremia develop insidiously because the brain adapts through generation of intracellular osmolytes (sorbitol, taurine) that maintain cellular hydration. However, acute or severe hypernatremia (Na+ >160 mEq/L) causes confusion, irritability, lethargy, seizures, and coma from cellular dehydration of neurons, particularly in infants and elderly patients.

Volume Status: Patients with maintained fluid access may appear euvolemic despite polyuria, as thirst-driven polydipsia replaces urinary losses. However, subtle signs of dehydration may be present: dry mucous membranes (though often mitigated by frequent fluid intake), decreased skin turgor, orthostatic hypotension, tachycardia. In infants or if fluid access is restricted, signs of hypovolemia predominate: sunken fontanelle, sunken eyes, poor skin turgor, weak cry.

Neurologic Findings (if hypernatremia present): Irritability, lethargy, confusion, hyperthermia, hyperreflexia, or seizures indicate significant hypernatremia. Focal neurologic deficits (hemiparesis, aphasia) suggest osmotic demyelination syndrome from overly rapid correction of chronic hypernatremia.

Findings Related to Underlying Etiology: In central DI from pituitary tumors, visual field defects (bitemporal hemianopsia from craniopharyngioma), headache, or other pituitary hormone deficiencies may be present. In sarcoidosis-related DI, pulmonary findings, uveitis, or erythema nodosum may be noted. In nephrogenic DI from lithium, signs of chronic kidney disease or hypercalc

Contraindicated/pitfalls: desmopressin is ineffective in nephrogenic DI and dangerous in primary polydipsia (severe hyponatremia); ACE inhibitors and other agents are irrelevant here; never abruptly stop lithium without psychiatric input; gestational DI responds to desmopressin but not to native vasopressin, which placental vasopressinase destroys.